Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Kupper

Showing results (31-40 of 53) with videos related to

Pageof 6
Sort By:
Experimental Pathology|January 1, 1987
Involvement of the central nervous system in malignant lymphomas of miceH Kupper, H Gerlach, H Wessel, et al.
British Journal of Cancer|May 6, 1998
Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancerM Lehnert, K Mross, J Schueller, et al.
Arthritis and Rheumatism|May 21, 2013
Long-term efficacy of adalimumab after drug withdrawal and retreatment in patients with active non-radiographically evident axial spondyloarthritis who experience a flareH Haibel, F Heldmann, J Braun, et al.
Allergie Und Immunologie|January 1, 1984
[Characterization of a series of monoclonal antibodies against human T cells]H Fiebig, I Behn, R Gruhn, et al.
Annals of the Rheumatic Diseases|July 30, 2008
Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label studyM Rudwaleit, E Rødevand, P Holck, et al.
Rheumatology (Oxford, England)|January 5, 2008
Personal and economic burden of late-stage rheumatoid arthritis among patients treated with adalimumab: an evaluation from a patient's perspectiveT Mittendorf, B Dietz, R Sterz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 30, 2000
Relationship between interleukin-6 plasma concentration in patients with sepsis, monocyte phenotype, monocyte phagocytic properties, and cytokine productionA Spittler, M Razenberger, H Kupper, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1995
Dexverapamil as resistance modifier in acute myeloid leukaemiaR Pirker, S Zöchbauer, H Kupper, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 11, 2011
Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVEJ-P Ortonne, S Chimenti, K Reich, et al.
Annals of the Rheumatic Diseases|January 28, 2006
Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritisM H Schiff, G R Burmester, J D Kent, et al.
Pageof 6

Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
Experimental Pathology|January 1, 1987
Involvement of the central nervous system in malignant lymphomas of miceH Kupper, H Gerlach, H Wessel, et al.
British Journal of Cancer|May 6, 1998
Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancerM Lehnert, K Mross, J Schueller, et al.
Arthritis and Rheumatism|May 21, 2013
Long-term efficacy of adalimumab after drug withdrawal and retreatment in patients with active non-radiographically evident axial spondyloarthritis who experience a flareH Haibel, F Heldmann, J Braun, et al.
Allergie Und Immunologie|January 1, 1984
[Characterization of a series of monoclonal antibodies against human T cells]H Fiebig, I Behn, R Gruhn, et al.
Annals of the Rheumatic Diseases|July 30, 2008
Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label studyM Rudwaleit, E Rødevand, P Holck, et al.
Rheumatology (Oxford, England)|January 5, 2008
Personal and economic burden of late-stage rheumatoid arthritis among patients treated with adalimumab: an evaluation from a patient's perspectiveT Mittendorf, B Dietz, R Sterz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 30, 2000
Relationship between interleukin-6 plasma concentration in patients with sepsis, monocyte phenotype, monocyte phagocytic properties, and cytokine productionA Spittler, M Razenberger, H Kupper, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1995
Dexverapamil as resistance modifier in acute myeloid leukaemiaR Pirker, S Zöchbauer, H Kupper, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 11, 2011
Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVEJ-P Ortonne, S Chimenti, K Reich, et al.
Annals of the Rheumatic Diseases|January 28, 2006
Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritisM H Schiff, G R Burmester, J D Kent, et al.
Pageof 6